Key facts
- It has raised $14.4M; the latest was Later Stage VC in Jan 2026.
- Notable investors include Addor Capital, Shandong Finance Group, CITIC Medical & Heath Group, Shandong New Growth Drivers Fund Management.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Accurdx
- ·The full record, as it builds
Funding rounds
No funding rounds for Accurdx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Accurdx
Developer of in vitro diagnostic instruments and supporting reagents designed for clinical diagnosis. With hemostasis and thrombus detection as the core technology, the company's products include coagulation detection systems, specific protein detection systems, reproductive detection systems and immune detection systems, providing medical laboratories with accurate clinical diagnosis solutions.
- Sector
- Healthcare
- HQ
- Jinan, China
- Founded
- 2017
- Employees
- 57
- Website
- accurdx.com/
- Ownership
- Privately Held (backing)
Accurdx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Accurdx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Accurdx in its N-PORT filings yet. We sweep new filings monthly.